CUREAPP
2.11.2022 09:31:42 CET | Business Wire | Press release
CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) announces the start of insurance coverage for its CureApp HT Hypertension Adjunctive Treatment App (hereafter, CureApp HT), a DTx*1 solution treating hypertension, in Japan from September 1, 2022. Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005330/en/
Assisting Lifestyle Changes as a Treatment for Hypertension (Graphic: Business Wire)
After confirming the efficacy and safety of CureApp HT through clinical trials, the results of a Japanese Phase III domestic multicenter randomized controlled trial were published in EHJ, one of the most well-respected peer reviewed journals in the world in 2021. In April 2022, CureApp HT was the first digital therapeutics app for hypertension to receive government approval in the world, and the app has been covered by insurance since September 1. This marks the first case of a DTx treatment solution being covered by insurance in the field of hypertension in the world. Looking ahead, CureApp looks to pursue further commercialization efforts of this Japanese-led medical innovation. The impact of hypertension is seen beyond Japan’s borders, and efforts to correct patient lifestyle habits is a common theme across the globe. Therefore, CureApp also plans to proactively expand CureApp HT’s reach all over the world, beginning with the U.S.
Importance of lifestyle changes, current challenges, and the potential of CureAppHT
The Guidelines for the Management of Hypertension 2019 describes that “lifestyle changes are important because not only are they expected to produce a hypotensive effect, but also they prevent hypertension”. The guidelines also say that “lifestyle guidance should be provided to all patients with hypertension, because they could increase the hypotensive effect and reduce the dosage of antihypertensive drugs”. Despite this recommendation, there has been little uptake in such behavioral therapy due to the challenges presented in having patients implement lifestyle changes on a continual basis and limited time of doctor consultation sessions. It is also said that a certain period of guided intervention*2 is needed for lifestyle changes to take hold.
CureApp HT helps to connect doctors and patients, and promotes lifestyle changes that were previously difficult to maintain while ensuring to sustain modified behavior in patients.
*1 An abbreviation of Digital Therapeutics. Products with pharmaceutical approval for use as medical devices.
*2 Kamioka H, Nakamura Y, Yazaki T, Uebaba K, Mutoh Y, Okada S, Takahashi M. Comprehensive health education combining hot spa bathing and lifestyle education in middle-aged and elderly women: one-year follow-up on randomized controlled trial of three- and six-month interventions. J Epidemiol. 2006 Jan;16(1):35-44. doi: 10.2188/jea.16.35. PMID: 16369107; PMCID: PMC7560544.
Summary of clinical trials for this product
https://doi.org/10.1093/eurheartj/ehab559
About CureApp, Inc.
CureApp, Inc. is a MedTech venture that conducts research and development into the creation of medical device programs, which apply advanced software technology and medical evidence to treat illnesses, with the intent of manufacturing and distributing them. The Company is hard at work developing “therapeutic apps” - apps used to treat illnesses - in order to become the first in Japan to establish a new healthcare service centered on “producing a therapeutic effect to treat illnesses using an app”. In August 2020, CureApp was the first to receive medical device regulatory approval for a disease treatment app in Japan in the form of a nicotine addiction treatment app, which was later reimbursed under national health insurance in December of the same year.
Businesses CureApp is involved in
Nicotine addiction |
Received Medical Device Regulatory Approval in August 2020; reimbursed by National Healthcare insurance and prescriptions begin in December of the same year |
Hypertension |
Received Medical Device Regulatory Approval in April 2022 |
NASH (Nonalcoholic steato-hepatitis) |
Under joint development with Sawai Group Holdings Co. / Undergoing clinical trials with The University of Tokyo Hospital |
Alcohol addiction |
App currently in development with the National Hospital Organization Kurihama Medical and Addiction Center / Clinical trials underway at the Okayama City General Medical Center, Okayama City Hospital |
Oncology |
Treatment app for breast cancer patients currently in development with DAIICHI SANKYO COMPANY, LIMITED. |
Chronic heart failure |
App under development with our partners at the YUMINO Medical Corporation |
In addition to the above, we provide mobile health programs for private companies through our “ascure Smoking Cessation Program” and “Specific Health Guidance ascure Smoking Cessation Program”, which leverages the knowledge garnered in the development of these digital therapeutics for medical institutions. These programs have been implemented at over 230 companies and health insurance societies. Looking ahead, we will look to sequentially rolling out this “Japanese-developed digital health solution” worldwide based on the model established in Japan.
CureApp, Inc. Company Profile
Representative
|
Kohta Satake |
Head Office Address |
Kodenma-Cho YS building 4th floor 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan, 103-0001 |
U.S. Branch |
CureApp North America, Inc. |
Business activities |
Development of Software as a Medical Device (SaMD), mobile health-related services |
URL |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
